Early data from a clinical trial of Regeneron's drug linvoseltamab for light chain amyloidosis show promising results, with 90% of participants achieving a complete hematological response. This bispecific antibody targets malignant plasma cells, potentially offering a more effective treatment option compared to standard therapies currently used for this rare blood disorder.
Regeneron's drug linvoseltamab shows promising early data as a potential treatment for light chain amyloidosis, achieving a 90% complete hematological response in a small clinical trial. This bispecific antibody, already FDA-approved for multiple myeloma, targets BCMA and CD3 proteins to eradicate the disease-driving plasma cells and could represent a paradigm shift in treatment, with ongoing trials possibly paving the way for broader applications, including autoimmune diseases. For an investor or professional in healthtech, this could signal a strategic opportunity to explore Regeneron's expanding applications of linvoseltamab.